Mesoblast shares hit 7-year lows as Teva walks

By Brian Robins
Updated June 14 2016 - 5:34pm, first published 4:47pm
Mesoblast boss Silviu Itescu: a key US partner has surrendered all rights to its heart failure treatment.
 Photo: Josh Robenstone
Mesoblast boss Silviu Itescu: a key US partner has surrendered all rights to its heart failure treatment. Photo: Josh Robenstone

Shares in Mesoblast were dumped in sharemarket trading on Tuesday as a key research partner walked away from work on a treatment for chronic heart failure, the company's leading research program, in the biotechnology company's second significant setback in the past year.

Get the latest St George news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.